查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950512

镍钛诺血管重组器械市场（按产品类型、应用和最终用户划分），全球预测（2026-2032）

Nitinol Revascularization Device Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，镍钛合金再灌注装置市场规模将达到 20.4 亿美元，到 2026 年将达到 22.6 亿美元。预计到 2032 年将达到 42.5 亿美元，复合年增长率为 11.01%。

关键市场统计数据
基准年 2025 20.4亿美元
预计年份：2026年 22.6亿美元
预测年份 2032 42.5亿美元
复合年增长率 (%) 11.01%

镍钛合金再灌注装置的策略性入门指南：概述其临床作用、材料优势以及影响其临床应用的关键因素

由于其独特的材料特性和持续的器械创新，镍钛合金再灌注装置已从小众解决方案发展成为各种血管专科的核心工具。形状记忆和超弹性使其能够贴合复杂的解剖结构，从而拓展了其临床应用范围，从冠状动脉介入治疗扩展到神经血管和周边血管领域。因此，临床医生和采购团队越来越多地从多个角度评估器械的选择，包括输送性、径向强度、贴合度和长期血管相互作用。

技术进步、临床证据要求和基于价值的支付讯号如何融合，将重塑镍钛合金器械系列的采用和创新

技术的融合、临床指南的不断更新以及对成本效益的重新关注，正在推动镍钛合金再灌注装置领域发生变革性转变。小型化和改进的输送系统使得以往难以到达的解剖部位成为可能，而表面处理技术和药物释放型策略则缩小了自膨胀式装置和球囊扩张型之间的性能差距。这些技术进步正在改变临床医师的选择偏好，并开启了几年前还无法实现的全新手术方法。

2025 年美国关税的累积营运和采购影响正在迫使供应链重新设计，商业性重点重新调整。

2025年美国关税政策为镍钛合金再灌注装置的製造商和采购商带来了新的商业风险和营运调整。最直接的影响是，各机构需要重新评估筹资策略，权衡成本、供应连续性和替代来源的监管复杂性。许多相关人员采取的应对措施包括加快供应商资格认证流程和实现采购管道多元化，以减少对单一供应商的依赖。这导致人们更加重视供应商审核和品质认证的公正性。

基于细分的因素对产品开发、临床应用和采购的影响，将设备类别适用性和最终用户环境与策略重点连结起来。

了解镍钛合金再灌注治疗领域的细分市场对于制定合适的临床、商业性和监管策略至关重要。产品差异化始于两大类器械：球囊扩张型支架和自扩张式镍钛合金支架。球囊扩张型支架主要用于冠状动脉介入治疗和周边血管手术，在这些手术中，径向刚度和精确部署至关重要。自扩张式镍钛合金支架则适用于神经血管和周边血管解剖结构，这些部位需要支架具有柔软性和长期的贴合性。在周边血管手术中，膝下、股腘动脉和髂股动脉等不同血管的解剖结构和动态差异会影响器械的设计选择、耐久性预测以及手术辅助工具的使用。

区域法规环境、临床实践模式和基础设施现状决定了最适合美洲、欧洲、中东和非洲以及亚太地区的商业化方法。

区域趋势将显着影响全球市场镍钛合金再灌注装置的监管路径、临床应用和商业化策略。在美洲，法规结构已相当完善，支付者也越来越重视基于可靠的临床结果和成本效益进行报销。这迫使製造商优先考虑产生高品质的实证医学证据并建立高效的经销伙伴。在培训和操作支援方面进行投入，通常是增强临床医生信心并将其融入心臟病学和血管外科治疗路径的关键因素。

从企业层面的竞争与合作观点，着眼于技术差异化，展现了塑造市场定位的伙伴关係与营运能力。

镍钛合金再灌注领域的企业竞争体现在创新策略、临床伙伴关係以及市场推广的差异化。一些製造商专注于平台工程，整合新一代输送系统和先进的影像相容性，以实现临床疗效的逐步提升和手术效率的提高。另一些製造商则优先考虑表面处理、药物释放型技术和聚合物整合，以解决血管再阻塞和长期血管癒合问题，这需要持续投入临床试验和上市后监测。

针对製造商、医疗系统和经销商的具体策略：建立具有韧性的价值链，以加速临床应用并向支付方证明其价值

产业领导者应采取一系列切实可行的倡议，将洞察转化为临床、商业和营运领域的竞争优势。首先，应优先开发模组化平台，该平台能够支援多种镍钛合金形式和治疗适应症，并采用单一给药系统，从而降低生产复杂性，减轻临床医生的培训负担。其次，应投资于有针对性的真实世界证据项目和註册登记，以解答支付方最关心的问题，并产生持续医保谈判所需的长期安全性数据。

一种透明且可重复的调查方法，结合文献综述、专家访谈和供应链分析，以检验研究结果及其意义。

本分析所依据的研究采用了混合方法，以确保研究的稳健性、多方验证和透明度。二手资料收集利用了同行评审的临床文献、监管文件和医疗设备认证摘要，以梳理临床证据和核准途径。专利格局分析和产品标籤审查确定了技术差异和主张依据，而公共采购文件和医院采购政策则提供了有关定价和竞标条款的见解。

综合考虑临床、技术和商业性因素，以确定哪些镍钛合金器械能够获得持续应用和策略优势。

透过整合临床进展、政策阻力和商业策略，我们可以清楚地整体情况：镍钛合金再灌注装置仍然是现代血管治疗的核心，但其成功需要产品设计、证据产生和供应链管理等方面的整合思考。材料科学的进步和输送系统的改进拓展了临床应用的可能性，而监管机构的期望和支付方的审查则要求提供可靠的长期数据并提高手术效率。因此，能够协调技术创新、实用临床研究和强大的供应链韧性的机构，将更有能力将装置的潜力转化为持续的临床应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 镍钛诺血管重组器械市场（依产品类型划分）

  • 球囊扩张型支架
    • 冠状动脉支架
    • 末梢用支架
  • 自膨式镍钛合金支架
    • 神经血管支架
    • 末梢用支架

9. 依应用分類的镍钛诺血管重组器械市场

  • 冠状动脉疾病
  • 神经血管
  • 周边动脉疾病
    • 膝盖以下
    • 股腘动脉
    • 髂股动脉

第十章 依最终用户分類的镍钛诺血管重组器械市场

  • 门诊手术中心
  • 医院
  • 专科诊所

11. 镍钛诺血管重组器械市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 镍钛诺血管重组器械市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国镍钛诺血管重组器械市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

14. 美国镍钛合金血管重组器械市场

第十五章 中国镍钛合金血管重组器械市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Admedes Schuessler GmbH
  • AngioDynamics, Inc.
  • Becton, Dickinson and Company
  • Bentley InnoMed GmbH
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CR Bard, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Elixir Medical Corporation
  • ELLA-CS
  • Endologix, Inc.
  • Johnson & Johnson
  • JOTEC GmbH
  • Lombard Medical, Inc.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort NeuroTech
  • Nipro Corporation
  • Penumbra, Inc.
  • Stryker Corporation
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-4F7A6D4FD8AF

The Nitinol Revascularization Device Market was valued at USD 2.04 billion in 2025 and is projected to grow to USD 2.26 billion in 2026, with a CAGR of 11.01%, reaching USD 4.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.04 billion
Estimated Year [2026] USD 2.26 billion
Forecast Year [2032] USD 4.25 billion
CAGR (%) 11.01%

A strategic primer on nitinol revascularization devices outlining clinical roles, material advantages, and the critical factors shaping clinical adoption

Nitinol revascularization devices have evolved from niche solutions into central tools across diverse vascular specialties, driven by unique material properties and continuous device innovation. Shape memory and superelasticity enable designs that conform to complex anatomies, which in turn have broadened clinical indications from coronary interventions to neurovascular and peripheral applications. As a result, clinicians and procurement teams increasingly evaluate device selection through a combined lens of deliverability, radial strength, conformability, and long-term vessel interaction.

Alongside clinical performance, regulatory scrutiny and reimbursement environments are influencing how new iterations move from concept to clinic. Advances in imaging, deployment systems, and adjunctive therapies are converging to reduce procedural times and improve lesion coverage, which incentivizes adoption among interventional cardiology, neurointerventional, and vascular surgery teams. Consequently, stakeholders must balance procedural benefits against capital and disposable costs, while anticipating evolving clinical evidence that redefines best practices.

Moving forward, the introduction of novel alloy formulations, refined surface treatments, and integrated delivery platforms will determine which products gain traction. Strategic leaders should therefore view nitinol revascularization devices not merely as consumables but as technology platforms that interact with clinical workflows, training needs, and long-term patient outcomes.

How converging technological advances clinical evidence requirements and value-based payment signals are reshaping adoption and innovation of nitinol device portfolios

The landscape for nitinol revascularization devices is undergoing transformative shifts driven by technological convergence, shifting clinical guidelines, and a renewed focus on cost-effectiveness. Miniaturization and improved delivery systems are enabling access to previously challenging anatomies, while surface engineering and drug-eluting strategies are narrowing the performance gap between self-expanding and balloon-expandable formats. These technical advances are altering clinician preference hierarchies and opening new procedural approaches that were not feasible a few years ago.

Concurrently, regulatory frameworks in multiple jurisdictions are emphasizing real-world evidence and post-market surveillance, prompting manufacturers to invest more heavily in registries and longitudinal studies. This emphasis on longitudinal data is shaping device lifecycles and market entry strategies, with an increased premium on predictable clinical outcomes. Payer policies are also evolving to reward demonstrable value, thereby aligning commercial success with quantifiable improvements in patient outcomes and procedural efficiency.

In addition, patient-centered care models and multidisciplinary treatment teams are promoting integrated solutions that combine device design with procedural training, remote monitoring, and bundled payment pilot programs. As a consequence, successful companies are those that blend engineering excellence with clinical partnerships, evidence generation, and end-user education to achieve durable adoption.

The cumulative operational and procurement impacts of the 2025 United States tariff actions that are forcing supply chain redesign and commercial reprioritization

United States tariff measures implemented in 2025 introduced a new dimension of commercial risk and operational recalibration for manufacturers and purchasers of nitinol revascularization devices. The most immediate consequence has been a reassessment of procurement strategies as organizations weigh the trade-offs between cost, continuity of supply, and the regulatory complexity of alternative sources. Many stakeholders responded by accelerating supplier qualification processes and diversifying procurement to reduce single-source dependencies, which in turn increased the emphasis on supplier audits and quality-certification alignment.

Manufacturers have re-evaluated production footprints in response, considering partial nearshoring, increased local assembly, or contractual commitments with regional manufacturing partners to mitigate tariff exposure. These moves have consequences for lead times, inventory models, and capital allocation; firms that can adapt manufacturing and distribution models while preserving quality standards are gaining competitive resilience. Meanwhile, trading partners and component suppliers adjusted commercial terms and delivery schedules to retain business, which required active negotiation and contractual flexibility.

From a demand perspective, healthcare systems have become more rigorous in tender specifications, incorporating total-cost-of-ownership considerations that include tariff-influenced logistics and warranty impacts. The net effect is an industry-wide push toward supply chain transparency, scenario planning, and strategic collaboration between purchasers and manufacturers to stabilize access to critical nitinol technologies.

Segmentation-driven implications for product development clinical adoption and procurement that connect device class application targets and end-user settings to strategic priorities

Understanding segmentation is essential for tailoring clinical, commercial, and regulatory strategies across the nitinol revascularization landscape. Product differentiation begins with two primary device classes: balloon expandable stents and self-expanding nitinol stents. Balloon expandable stents are predominantly used in coronary interventions and in peripheral applications where radial rigidity and precise deployment are paramount, while self-expanding nitinol stents serve neurovascular indications and peripheral anatomies that demand flexibility and chronic conformability. Within the peripheral category, anatomical and biomechanical distinctions between below-the-knee, femoropopliteal, and iliofemoral segments influence device design choices, longevity expectations, and procedural adjuncts.

Application-driven segmentation further clarifies clinical value propositions. Coronary artery disease treatment emphasizes deliverability in tortuous vessels and optimal scaffold support, neurovascular use cases prioritize atraumatic profiles and radiopacity for intracranial navigation, and peripheral artery disease treatment requires nuanced strategies depending on lesion location and patient mobility. Below-the-knee lesions demand fine-caliber devices that withstand flexion, femoropopliteal territories require resistance to external compression and torsion, and iliofemoral segments benefit from stents that balance large-vessel radial strength with conformability.

End-user segmentation also ensures deployment strategies match clinical settings. Ambulatory surgical centers, hospitals, and specialty clinics have differing procedural volumes, resource availability, and procurement cycles, which affects device selection, inventory management, and training investments. Recognizing how product type, clinical application, and care setting intersect enables more precise commercialization, clinical evidence planning, and education programs tailored to user-specific needs.

How regional regulatory environments clinical practice patterns and infrastructure realities across the Americas EMEA and Asia-Pacific dictate tailored commercialization approaches

Regional dynamics materially shape regulatory pathways, clinical adoption, and commercialization strategies for nitinol revascularization devices across global markets. In the Americas, regulatory frameworks are well established and payers increasingly tie reimbursement to robust clinical outcomes and cost-effectiveness, prompting manufacturers to prioritize high-quality evidence generation and streamlined distribution partnerships. Investment in training and procedural support is often decisive in building clinician confidence and pathway integration across both cardiology and vascular surgery communities.

In Europe Middle East and Africa, heterogeneous regulatory environments and variable healthcare infrastructure create both opportunities and complexities. Manufacturers often adopt regionally nuanced market entry strategies that combine CE or notified body approvals with country-specific evidence generation, while strategic partnerships with regional distributors and clinical centers accelerate adoption in capacity-constrained environments. Reimbursement variability in this region means that demonstrating clear clinical benefit and procedural efficiency is frequently more important than price alone.

In Asia-Pacific, rapid modernization of healthcare infrastructure, high procedural volumes, and a growing emphasis on domestic manufacturing capacity are driving significant activity. Regulatory agencies across the region are increasingly aligning to international standards while encouraging local trials and post-market surveillance. For many companies, Asia-Pacific represents both a testing ground for scalable innovations and a focal point for manufacturing and supply-chain investments aimed at global resilience.

Competitive and collaborative company-level perspectives focusing on technological differentiation evidence partnerships and operational capabilities that shape market positioning

Competitive dynamics among companies in the nitinol revascularization space are defined by differentiated approaches to innovation, clinical partnership, and go-to-market execution. Some manufacturers emphasize platform engineering, integrating next-generation delivery systems with advanced imaging compatibility to deliver incremental clinical improvements and procedural efficiencies. Others prioritize surface treatments, drug-eluting technologies, and polymer integration to address restenosis and long-term vessel healing, which requires sustained investment in clinical trials and post-market surveillance.

Collaborative models are gaining traction as well, where established device firms form alliances with startup innovators, imaging companies, and academic centers to accelerate translational research and shorten development cycles. Strategic M&A and licensing deals are used to fill technological gaps, expand anatomical coverage, or access regional distribution networks. Meanwhile, companies that invest in robust clinical education programs and center-of-excellence collaborations tend to achieve faster procedural uptake and longer-term clinician advocacy.

Quality systems and regulatory acumen remain differentiators; firms that maintain transparent supply chains, proactive vigilance systems, and disciplined regulatory submissions reduce approval friction and strengthen customer trust. Ultimately, success is achieved by balancing engineering differentiation with evidence generation, manufacturing reliability, and end-user support.

Actionable strategies for manufacturers health systems and distributors to build resilient supply chains accelerate clinical adoption and demonstrate payer-relevant value

Industry leaders should pursue a set of pragmatic actions to translate insight into competitive advantage across clinical, commercial, and operational domains. First, prioritize modular platform development that allows a single delivery system to support multiple nitinol geometries and therapeutic indications, thereby reducing manufacturing complexity and easing clinician training burdens. Second, invest in targeted real-world evidence programs and registries that address the most pressing payer questions and generate longitudinal safety data needed for durable reimbursement conversations.

Third, redesign procurement and supply-chain strategies to incorporate tariff sensitivity, dual sourcing, and regional assembly options that reduce exposure to policy shifts and logistics disruptions. Fourth, align commercialization efforts with specific end-user workflows by offering procedure-centric training, simulation, and hands-on proctoring that demonstrably shorten learning curves and improve outcomes. Fifth, establish strategic partnerships with imaging and analytics providers to create integrated procedural ecosystems that enhance device value and create stickiness with clinical customers.

Collectively, these measures strengthen resilience, accelerate adoption, and protect margins. Executed together, they enable organizations to respond to regulatory change, demonstrate value to payers, and preserve access for clinicians and patients.

A transparent and replicable methodological framework combining literature synthesis expert interviews and supply-chain analysis to validate insights and implications

The research underpinning this analysis used a mixed-methods approach to ensure robustness, triangulation, and transparency. Secondary data collection included peer-reviewed clinical literature, regulatory filings, and device clearance summaries to map clinical evidence and approval pathways. Patent landscaping and product labeling reviews were used to identify technological differentiators and claims substantiation, while public procurement documents and hospital purchasing policies informed pricing and tender considerations.

Primary research incorporated structured interviews with practicing interventionalists, vascular surgeons, procurement leaders, and regulatory experts to validate clinical priorities and device selection criteria. Manufacturer discussions and supply-chain conversations provided operational insight into manufacturing constraints, qualification timelines, and logistics. Data synthesis prioritized cross-validation; where secondary signals suggested a trend, primary respondents were consulted to confirm practical implications and timing. Analytical steps included thematic coding of qualitative inputs, comparative device feature matrices, and scenario analysis for tariff and supply disruption impacts.

Quality assurance processes included independent peer review by clinical and industry advisors, audit trails for sourced documents, and consistency checks across datasets to minimize bias. The methodology emphasizes replicability and clear documentation, enabling stakeholders to trace findings back to source evidence and expert corroboration.

Synthesis of clinical technological and commercial forces that determine which nitinol devices will achieve durable adoption and strategic advantage

Bringing together clinical evolution, policy headwinds, and commercial strategy yields a cohesive picture: nitinol revascularization devices remain central to contemporary vascular care, but success requires integrated thinking across product design, evidence generation, and supply-chain management. Material science advances and delivery-system refinements expand clinical possibilities, yet regulatory expectations and payer scrutiny mandate credible long-term data and procedural efficiency gains. Consequently, organizations that synchronize engineering innovation with pragmatic clinical studies and robust supply resilience will be best positioned to translate device potential into sustained clinical adoption.

Regional nuances and end-user requirements underscore the need for adaptable commercialization models: what succeeds in high-volume tertiary centers may not transfer directly to ambulatory or specialty clinic settings without tailored training and evidence. Tariff-driven supply shocks in 2025 crystallized the importance of diversified sourcing and flexible manufacturing footprints, accelerating strategic shifts that were already under way. Moving forward, the convergence of integrated procedural ecosystems, real-world evidence, and patient-centered outcomes will determine which products achieve scale.

Ultimately, the path to leadership in the nitinol device space lies in balancing technical differentiation with operational excellence, aligning product roadmaps with payer expectations, and maintaining close clinical partnerships that drive repeatable, measurable improvements in care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nitinol Revascularization Device Market, by Product Type

  • 8.1. Balloon Expandable Stent
    • 8.1.1. Coronary Stent
    • 8.1.2. Peripheral Stent
  • 8.2. Self Expanding Nitinol Stent
    • 8.2.1. Neurovascular Stent
    • 8.2.2. Peripheral Stent

9. Nitinol Revascularization Device Market, by Application

  • 9.1. Coronary Artery Disease
  • 9.2. Neurovascular
  • 9.3. Peripheral Artery Disease
    • 9.3.1. Below The Knee
    • 9.3.2. Femoropopliteal
    • 9.3.3. Iliofemoral

10. Nitinol Revascularization Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Nitinol Revascularization Device Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Nitinol Revascularization Device Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Nitinol Revascularization Device Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Nitinol Revascularization Device Market

15. China Nitinol Revascularization Device Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Admedes Schuessler GmbH
  • 16.7. AngioDynamics, Inc.
  • 16.8. Becton, Dickinson and Company
  • 16.9. Bentley InnoMed GmbH
  • 16.10. Biotronik SE & Co. KG
  • 16.11. Boston Scientific Corporation
  • 16.12. C. R. Bard, Inc.
  • 16.13. Cook Medical LLC
  • 16.14. Edwards Lifesciences Corporation
  • 16.15. Elixir Medical Corporation
  • 16.16. ELLA-CS
  • 16.17. Endologix, Inc.
  • 16.18. Johnson & Johnson
  • 16.19. JOTEC GmbH
  • 16.20. Lombard Medical, Inc.
  • 16.21. Medtronic plc
  • 16.22. Merit Medical Systems, Inc.
  • 16.23. MicroPort NeuroTech
  • 16.24. Nipro Corporation
  • 16.25. Penumbra, Inc.
  • 16.26. Stryker Corporation
  • 16.27. Terumo Corporation
  • 16.28. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BELOW THE KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BELOW THE KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BELOW THE KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY ILIOFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY ILIOFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY ILIOFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 121. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 122. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 142. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 143. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 149. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 150. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)